Treat-to-target comparison between once daily biphasic insulin aspart 30 and insulin glargine in Chinese and Japanese insulin-naïve subjects with type 2 diabetes

Author： Yang Wenying   Xu Xiangjin   Liu Xiaomin   Yang Gangyi   Seino Yutaka   Andersen Henning   Jinnouchi Hideaki  

Publisher： Informa Healthcare

ISSN： 1473-4877

Source： Current Medical Research and Opinion, Vol.29, Iss.12, 2013-12, pp. : 1599-1608

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Once-daily initiation with biphasic insulin aspart 30 versus insulin glargine in patients with type 2 diabetes inadequately controlled with oral drugs: an open-label, multinational RCT

By Strojek Krzysztof   Bebakar Wan M.W.   Khutsoane Duma T.   Pesic Milica   Šmahelová Alena   Thomsen Henrik F.   Kalra Sanjay  

Current Medical Research and Opinion, Vol. 25, Iss. 12, 2009-12 ,pp. : 2887-2894

Informa Healthcare

Access to resources Recommend Favorite

Comments and reply on: Long-term clinical and cost outcomes of treatment with biphasic insulin aspart 30/70 versus insulin glargine in insulin-naïve type 2 diabetes patients: cost-effectiveness analysis in the UK setting

By Currie Craig J.   McEwan Phil   Poole Chris   Valentine William J.   Palmer Andrew J.   Lammert Morten   Nicklasson Lars   Foos Volker   Roze Stéphane  

Current Medical Research and Opinion, Vol. 22, Iss. 5, 2006-05 ,pp. : 967-969

Informa Healthcare

Access to resources Recommend Favorite

Once-daily insulin detemir in a cohort of insulin-naïve patients with type 2 diabetes: a sub-analysis from the PREDICTIVE study

By Meneghini L. F.   Dornhorst A.   Sreenan S.  

Current Medical Research and Opinion, Vol. 25, Iss. 4, 2009-04 ,pp. : 1029-1035

Informa Healthcare

Access to resources Recommend Favorite

Long-term clinical and cost outcomes of treatment with biphasic insulin aspart 30/70 versus insulin glargine in insulin naïve type 2 diabetes patients: cost-effectiveness analysis in the UK setting

By Valentine William J.   Palmer Andrew J.   Lammert Morten   Nicklasson Lars   Foos Volker   Roze Stéphane  

Current Medical Research and Opinion, Vol. 21, Iss. 12, 2005-12 ,pp. : 2063-2071

Informa Healthcare

Access to resources Recommend Favorite

Intensifying insulin regimen after basal insulin optimization in adults with type 2 diabetes: a 24‐week, randomized, open‐label trial comparing insulin glargine plus insulin glulisine with biphasic insulin aspart (LanScape)

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 17, Iss. 12, 2015-12 ,pp. : 1133-1141

John Wiley & Sons Inc

Access to resources Recommend Favorite